Please upgrade your browser.
Gurkamal Chatta, MD, professor of oncology and chief of genitourinary oncology at Roswell Park Cancer Institute in Buffalo, New York, said that improved understanding of kidney cancer is long overdue.
S-TRAC is the First RCC Trial of a Tyrosine Kinase Inhibitor to Prolong Disease-Free Survival in the Adjuvant Setting
Send for your FREE orange awareness ribbon and share the image, too!
A small phase II study highlights modest efficacy and a concerning safety profile associated with this compound in patients with metastatic RCC.
Knowing what questions to ask is critically important to your care,
Young Investigator Awards (YIA) sponsored by the Conquer Cancer Foundation and the Kidney Cancer Association
The Phase 3 trial is expected to enroll approximately 322 patients with recurrent or metastatic RCC who have failed at least two prior regimens, including VEGFR-TKI therapy (other than sorafenib).
U.S. Food and Drug Administration (FDA) approved Lenvima (lenvatinib, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma...
The U.S. FDA has granted CRLX101 Orphan Drug designation for the treatment of ovarian cancer and Fast Track designation in combination with Avastin® in metastatic renal cell carcinoma.
CABOMETYX, which was granted Fast Track and Breakthrough Therapy designations by the FDA, is the first therapy to demonstrate in a phase 3 trial for patients with advanced RCC, robust and clinically meaningful improvements in all three key efficacy parameters...
|Powered by NeonCRM|